Wet age-related macular degeneration research hub
4 indexed studies · 1 currently recruiting
- completed
Can deep phenotyping using retinal images predict response to intravitreal aflibercept therapy in patients with neovascular age-related macular degeneration?
Wet age-related macular degeneration (wet AMD) is commonly treated with eye injections called aflibercept. This study explores whether artificial intelligence (AI) can look at routine eye scans to predict which patients will respond best to the medicine, helping doctors provide clearer and more personalised information right from the start.
United Kingdom · England - recruitingPhase I
An early-stage study to see if U8:ranibizumab eye drops are safe, well-tolerated, and effective for patients with a specific eye condition called choroidal neovascularisation
This study tests new eye drops for wet AMD, a condition causing central vision loss. It checks if the drops are safe, work well, and are better than injections. We're looking for adults aged 60+ with wet AMD to join.
United Kingdom · England - active not recruitingPHASE3
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
This study is testing a new, one-time gene therapy called ABBV-RGX-314 for wet age-related macular degeneration (wet AMD). It aims to see if this treatment can improve vision and reduce the need for frequent eye injections, compared to the standard treatment, aflibercept (EYLEA®).
United States · Canada · France - active not recruitingPHASE3
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56
This study, called LUCIA, is looking at a new treatment called EYP-1901 for wet age-related macular degeneration (wAMD). Researchers want to see if EYP-1901 is as effective as a standard treatment, aflibercept, over two years for improving or maintaining eyesight.
United States · Brazil · Czechia